Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Fintertech, a subsidiary of Daiwa Securities, launches bitcoin-backed yacht purchase loan service

Fintertech, a subsidiary of Daiwa Securities, launches bitcoin-backed yacht purchase loan service

ChaincatcherChaincatcher2025/10/20 03:50
Show original

ChainCatcher news, Fintertech, a subsidiary of Daiwa Securities Group, announced that it has begun offering digital asset-backed loans to buyers of the "NOT A GARAGE" shared high-end transportation service.

Users holding bitcoin (BTC) or ethereum (ETH) can obtain funds to purchase private jets or yachts without selling their crypto assets. The actual annual interest rate for the first year of the loan is 0% - 3%, and from the second year onwards it is 3.2% - 6%. The maximum loan amount is 500 million yen, with a collateral ratio of 40%. Since October 1, Daiwa Securities has started introducing this loan service at its branches nationwide, further expanding the application scenarios of crypto assets in the high-end consumer sector.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.

U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).

智通财经2026/09/21 07:11

Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential

According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.

智通财经2026/09/21 07:11

Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.

TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).

智通财经2026/09/21 07:11